Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06040099 · ClinicalTrials.gov registry record · Phase 2

A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE

A Phase 2 study of Hepatocellular Carcinoma (HCC), sponsored by AstraZeneca.

Active
Registry status
Phase 2
Development phase
58
Enrollment target
20
Study locations

NCT06040099 is a Phase 2 study of Hepatocellular Carcinoma (HCC) that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 58 participants, below the 347-participant average among 15 other Hepatocellular Carcinoma (HCC) trials with a reported enrollment target (83% lower). The trial reports 20 study locations across 17 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06040099, a Phase 2 study of Hepatocellular Carcinoma (HCC), is active but no longer recruiting, sponsored by AstraZeneca.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
58 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to measure the efficacy and safety of durvalumab intravenous (IV) solution plus bevacizumab IV solution after transarterial radioembolization (Yttrium 90 glass microspheres TARE) in participants with unresectable hepatocellular carcinoma (HCC) amenable to embolization.

Conditions Studied

Hepatocellular Carcinoma (HCC)

Interventions

  • DRUG Bevacizumab
  • DRUG Durvalumab
  • PROCEDURE Transarterial Radioembolization (TARE)

Study Locations (20)

Florida

  • Research Site - Gainesville
  • Research Site - Orlando

Georgia

  • Research Site - Atlanta
  • Research Site - Atlanta

New York

  • Research Site - Buffalo
  • Research Site - New York

Colorado

  • Research Site - Aurora

Illinois

  • Research Site - Chicago

Massachusetts

  • Research Site - Boston

Michigan

  • Research Site - Detroit

Missouri

  • Research Site - St Louis

Trial Details

FieldValue
Enrollment Target 58 participants
Start Date 2024-02-13
Est. Completion 2026-07-01
Phase Phase 2

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06040099

The ClinicalTrials.gov registry entry for NCT06040099 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 347-participant average among 15 other Hepatocellular Carcinoma (HCC) trials with a reported enrollment target (83% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hepatocellular Carcinoma (HCC) appearing as the primary indexed condition, and to 3 interventions - of which Bevacizumab is the first listed.

NCT06040099 reports 20 study locations spanning 17 distinct geographic areas - top geographies include Florida, Georgia, New York.

Frequently Asked Questions

What is clinical trial NCT06040099 about?

NCT06040099 is a clinical study titled "A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE". The purpose of this study is to measure the efficacy and safety of durvalumab intravenous (IV) solution plus bevacizumab IV solution after transarterial radioembolization (Yttrium 90 glass microspheres TARE) in participants with unresectable hepatocellular carcinoma (HCC) amenable to embolization.

What is the current status of trial NCT06040099?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2024-02-13. Estimated completion is 2026-07-01.

What conditions does trial NCT06040099 study?

This clinical trial studies the following conditions: Hepatocellular Carcinoma (HCC).

What interventions are being tested in trial NCT06040099?

The interventions under investigation include: Bevacizumab (DRUG), Durvalumab (DRUG), Transarterial Radioembolization (TARE) (PROCEDURE).

Who is sponsoring clinical trial NCT06040099?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06040099 being conducted?

This trial has 20 study locations across Colorado, Florida, Georgia, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hepatocellular Carcinoma (HCC)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hepatocellular Carcinoma (HCC)

All registered trials for this condition

Colorado

All trials with a study site in Colorado

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.